Get the Stockscreener App
0.00
100.00%
-2.11
Aileron Therapeutics Inc stock is traded at $0.00, with a volume of 0.
It is down -100.00% in the last 24 hours and down -100.00% over the past month.
Aileron Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on developing a novel class of therapeutics for the treatment of cancer and other diseases. The company's lead product candidate, ALRN-6924 is a novel chemoprotective medicine to treat and protect healthy cells in patients with cancer that harbors p53 mutations to reduce or eliminate chemotherapy-induced side effects. The company currently has two product candidates in clinical development, LTI-03 and LTI-01, and multiple candidates in preclinical development focused on fibrosis indications.
See More
Previous Close:
$2.11
Open:
$0
24h Volume:
0
Relative Volume:
0.00
Market Cap:
$45.72M
Revenue:
-
Net Income/Loss:
$-12.94M
P/E Ratio:
0.00
EPS:
-2.84
Net Cash Flow:
$-13.83M
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-100.00%
1Y Performance:
-100.00%
1-Day Range:
$0.00
$0.00
1-Week Range:
$0.00
$0.00
52-Week Range:
$0.00
$4.40
Aileron Therapeutics Inc Stock (ALRN) Company Profile
Name
Aileron Therapeutics Inc
Sector
Industry
Phone
(737) 802-1989
Address
12407 N. MOPAC EXPY., AUSTIN, MA
Compare ALRN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALRN
Aileron Therapeutics Inc
|
0.00 | 45.72M | 0 | -12.94M | -13.83M | -2.84 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.19 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
603.58 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
656.65 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
273.55 | 32.98B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
254.16 | 26.92B | 3.81B | -644.79M | -669.77M | -6.24 |
Aileron Therapeutics Inc Stock (ALRN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-28-25 | Initiated | Rodman & Renshaw | Buy |
| Jul-24-17 | Initiated | BofA/Merrill | Buy |
| Jul-24-17 | Initiated | Jefferies | Buy |
| Jul-24-17 | Initiated | William Blair | Outperform |
Aileron Therapeutics Inc Stock (ALRN) Latest News
Rein Therapeutics Granted Two Patents Covering The Novel Formulation And Administration Methods Of Dry Powder LTI-03 For Treatment Of Respiratory Diseases - marketscreener.com
Rein Therapeutics Announces a Publication in Biomedicines on the Immunomodulatory and Anti-fibrotic Properties of a Caveolin-1-Related Peptide in IPF and PASC-F - PR Newswire
Rein Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - PR Newswire
RNTX stock touches 52-week low at $1.6 amid market challenges - Investing.com
Aileron Therapeutics, Inc. Announces New Appointments - MarketScreener
Peripheral T-cell Lymphoma Treatment Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Revenue, Statistics, Companies & Growth Analysis Report by DelveInsight - The Globe and Mail
Reflecting On Productivity Software Stocks’ Q4 Earnings: Dropbox (NASDAQ:DBX) - The Globe and Mail
Artivion (AORT): Buy, Sell, or Hold Post Q4 Earnings? - The Globe and Mail
Better Artificial Intelligence Stock: SoundHound AI vs. C3.ai - The Globe and Mail
Did Robinhood Just Say Checkmate to SoFi? - The Globe and Mail
Firing on All Cylinders: Benchmark (NYSE:BHE) Q4 Earnings Lead the Way - The Globe and Mail
Stocks in play: i-80 GOLD CORP. - The Globe and Mail
Lucid (LCID): Buy, Sell, or Hold Post Q4 Earnings? - The Globe and Mail
Are XPeng (XPEV) Traders Overpricing Options Ahead of Q4 Earnings? - The Globe and Mail
Will Gasoline Prices Head Higher During the 2025 Driving Season? - The Globe and Mail
Snowflake (SNOW) Q4 Earnings Report Preview: What To Look For - The Globe and Mail
Chemotherapy Induced Anemia Drugs Market 2032: EMA, PDMA, FDA Approvals, Clinical Trials, Medication, Prevalence, NDA Approvals, Therapies, and Companies by DelveInsight - The Globe and Mail
Chemotherapy Induced Anemia Drugs Market 2032: EMA, PDMA, FDA - openPR
Hypoxia Treatment Market to Witness Substantial Growth by 2031 | - openPR
Theratechnologies (NASDAQ:THTX) vs. Aileron Therapeutics (NASDAQ:ALRN) Head to Head Survey - Defense World
Aileron Therapeutics Reports Q3 2024 Financial Results - MSN
Lockheed Martin Earnings: What To Look For From LMT - The Globe and Mail
Aileron Therapeutics, Inc. announced that it has received $42 million in funding from a group of investors. - Marketscreener.com
Aileron straps in for 2025 with a new name: Rein Therapeutics - Fierce Pharma
Aileron Therapeutics and Advancium Health Network Announce an Exclusive Option Agreement for the Acquisition of ALRN-6924 for Retinoblastoma - Marketscreener.com
Aileron Therapeutics, Inc. Announces Board Changes - Marketscreener.com
Aileron Therapeutics, Inc. Announces Board Changes -April 01, 2019 at 06:16 am EDT - Marketscreener.com
Aileron Therapeutics to be Included in the Russell Microcap® Index - Marketscreener.com
Aileron Therapeutics Announces Appointments to Scientific Advisory Board -March 28, 2018 at 07:00 am EDT - Marketscreener.com
Aileron Therapeutics Announces the Promotion of Richard J. Wanstall to Chief Financial Officer and Treasurer - Marketscreener.com
Aileron Therapeutics Announces Board Appointments - Marketscreener.com
Aileron Therapeutics to Present at the Canaccord Genuity 44th Annual Growth Conference - Marketscreener.com
Aileron Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights - Marketscreener.com
Aileron Therapeutics, Inc. Announces Management Changes - Marketscreener.com
Aileron Therapeutics Announces Management Changes - Marketscreener.com
Aileron Therapeutics, Inc. Announces CEO Changes - Marketscreener.com
Aileron Therapeutics Announces Management Changes -September 06, 2018 at 09:10 am EDT - Marketscreener.com
Rein Therapeutics announces name change and new ticker By Investing.com - Investing.com Canada
Rein Therapeutics announces name change and new ticker - Investing.com
Aileron Therapeutics announces rebranding to Rein Therapeutics - MSN
Geode Capital Management LLC Grows Position in Aileron Therapeutics, Inc. (NASDAQ:ALRN) - Defense World
Geode Capital Management LLC Boosts Stock Position in Pro-Dex, Inc. (NASDAQ:PDEX) - Defense World
Aileron Therapeutics Announces Rebranding to Rein Therapeutics - PR Newswire
Aileron Rebrands as Rein Therapeutics Following Breakthrough IPF Drug Trial Success - Stock Titan
Aileron Therapeutics to Present at the 8th Annual IPF Summit - The Eastern Progress Online
Aileron Therapeutics CEO James Brian Windsor buys $897 in stock By Investing.com - Investing.com Nigeria
Aileron Therapeutics CEO James Brian Windsor buys $897 in stock - Investing.com
Aileron Therapeutics Completes Enrollment in Cohort 2 of the Ongoing Phase 1b Clinical Trial Evaluating LTI-03 in Idiopathic Pulmonary Fibrosis (IPF) - The Eastern Progress Online
Aileron Therapeutics, Inc. (NASDAQ:ALRN) Sees Significant Decrease in Short Interest - MarketBeat
Chemotherapy Induced Anemia Treatment Market 2032: Clinical Trials, Medication, Prevalence, Incidence, Therapies, EMA, PDMA, FDA Approvals, and Companies by DelveInsight - Barchart
Aileron Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights - Citizentribune
Aileron Therapeutics Inc Stock (ALRN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.39%
3.66%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):